Frontiers in Immunology (Jan 2022)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

  • Alejandro Escobar,
  • Felipe E. Reyes-López,
  • Felipe E. Reyes-López,
  • Felipe E. Reyes-López,
  • Mónica L. Acevedo,
  • Luis Alonso-Palomares,
  • Fernando Valiente-Echeverría,
  • Ricardo Soto-Rifo,
  • Hugo Portillo,
  • Jimena Gatica,
  • Ivan Flores,
  • Estefanía Nova-Lamperti,
  • Carlos Barrera-Avalos,
  • María Rosa Bono,
  • Leonardo Vargas,
  • Valeska Simon,
  • Elias Leiva-Salcedo,
  • Cecilia Vial,
  • Juan Hormazabal,
  • Lina Jimena Cortes,
  • Daniel Valdés,
  • Ana M. Sandino,
  • Mónica Imarai,
  • Claudio Acuña-Castillo

DOI
https://doi.org/10.3389/fimmu.2021.766278
Journal volume & issue
Vol. 12

Abstract

Read online

CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.

Keywords